Application Prospects of Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia and the Challenges Encountered

Area of Science:

• Neonatal Medicine
• Regenerative Medicine
• Pulmonology

Background:

• Bronchopulmonary dysplasia (BPD) is a prevalent chronic lung disease in premature infants, leading to significant lung and neurological deficits.
• Current BPD treatments are limited, with insufficient efficacy and potential side effects, highlighting the need for novel therapeutic approaches.
• BPD negatively impacts long-term prognosis and can cause developmental delays in affected children.

Purpose of the Study:

• To review the potential of mesenchymal stem cell (MSC) therapy in treating bronchopulmonary dysplasia (BPD).
• To discuss the advantages, research progress, and challenges associated with MSC therapy for BPD.
• To evaluate the current status of MSCs as a therapeutic option for BPD.

Main Methods:

• Review of existing literature on stem cell therapy, specifically MSCs, for BPD treatment.
• Analysis of experimental trial data demonstrating the efficacy of MSCs in preclinical models.
• Examination of the mechanisms by which MSCs exert therapeutic effects, including anti-inflammatory, anti-fibrotic, and anti-oxidative properties.

Main Results:

• MSCs demonstrate potential in repairing damaged lung tissue by reducing inflammation, fibrosis, and oxidative stress.
• Experimental studies indicate that MSCs offer a promising therapeutic avenue for BPD.
• The review highlights the benefits of MSCs in addressing the underlying pathology of BPD.

Conclusions:

• MSC therapy presents a promising approach for BPD treatment due to its tissue-repairing capabilities.
• Challenges remain, including potential tumor formation, cell population heterogeneity, and ethical considerations.
• Extensive further research is required to establish the safety and efficacy of MSC therapy for BPD approval.